HYL Stock Overview
Engages in the research, development, and manufacture of pharmaceutical products to address unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Hyloris Pharmaceuticals SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.18 |
| 52 Week High | €13.30 |
| 52 Week Low | €2.89 |
| Beta | 0.45 |
| 11 Month Change | -15.08% |
| 3 Month Change | -21.52% |
| 1 Year Change | -58.89% |
| 33 Year Change | -66.14% |
| 5 Year Change | n/a |
| Change since IPO | -50.14% |
Recent News & Updates
Shareholder Returns
| HYL | BE Pharmaceuticals | BE Market | |
|---|---|---|---|
| 7D | 12.4% | -3.0% | -1.6% |
| 1Y | -58.9% | 4.3% | 2.0% |
Return vs Industry: HYL underperformed the Belgian Pharmaceuticals industry which returned 3.6% over the past year.
Return vs Market: HYL underperformed the Belgian Market which returned 2.7% over the past year.
Price Volatility
| HYL volatility | |
|---|---|
| HYL Average Weekly Movement | 14.9% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in BE Market | 6.3% |
| 10% least volatile stocks in BE Market | 2.1% |
Stable Share Price: HYL's share price has been volatile over the past 3 months compared to the Belgian market.
Volatility Over Time: HYL's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 41 | Stijn Van Rompay | hyloris.com |
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address unmet medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen sodium dihydrate used for post-operative pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortality associated with an emergency cardiac event, such as myocardial infarction or stroke; Milrinone ER for right heart failure due to left ventricular device; Dofetilide IV to treat atrial fibrillation; Metolazone IV for the treatment of salt and water retention, including edema accompanying congestive heart failure and renal diseases; and HY-075 IV to prevent and treat cardiovascular diseases.
Hyloris Pharmaceuticals SA Fundamentals Summary
| HYL fundamental statistics | |
|---|---|
| Market cap | €112.00m |
| Earnings (TTM) | -€13.24m |
| Revenue (TTM) | €6.94m |
20.9x
P/S Ratio-11.0x
P/E RatioIs HYL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HYL income statement (TTM) | |
|---|---|
| Revenue | €6.94m |
| Cost of Revenue | €155.00k |
| Gross Profit | €6.79m |
| Other Expenses | €20.03m |
| Earnings | -€13.24m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 20, 2025
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 97.77% |
| Net Profit Margin | -190.79% |
| Debt/Equity Ratio | 0.3% |
How did HYL perform over the long term?
See historical performance and comparison